Partner David Rosen was quoted in a Memphis Business Journal article, “A COVID-19 vaccine this year? It’s a long shot, but it’s possible,” about drug companies considering the use of a little-known regulatory tool to push their COVID-19 vaccines into Americans’ hands before the end of the year.
Rosen, who chairs the firm’s FDA regulatory practice, said the government’s decision to enact the Public Readiness and Emergency Preparedness (PREP) Act in response to the COVID-19 outbreak limits the legal repercussions that drugmakers could face if their COVID-19 products cause physical injury, death and other ill effects to users.
(Subscription required.)
People
Related News
30 May 2024
In the News
Donald Schroeder on EEOC Data Spike – 'There's more awareness'
Foley & Lardner LLP partner Donald Schroeder commented on the U.S. Equal Employment Opportunity Commission's (EEOC) recently published discrimination charge data for fiscal year 2023 in the Law360 article, "3 Factors That May Underlie EEOC Color Bias Charge Spike."
30 May 2024
In the News
Monica Chmielewski and Alexandra Maulden Author Overview of FDA Diversity-Related Documents for Clinical Trials
Foley & Lardner LLP partner Monica Chmielewski and associate Alexandra Maulden highlight the key takeaways of several U.S. Food and Drug Administration (FDA) diversity-related guidance documents from 2016 onwards in their Applied Clinical Trials article, “An Overview of FDA Diversity-Related Documents for Clinical Trials.”
28 May 2024
In the News
Anil Shankar Quoted on Pharma Decision, Impact on 340B Drug Pricing
Foley & Lardner LLP partner Anil Shankar offers insight on a recent decision which held that the federal 340B drug pricing program does not bar pharmaceutical drug manufacturers from imposing contractual conditions on contract pharmacies in the Law360 article, "DC Circ. Decision May Lead To Tighter 340B Pharma Contracts."